Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025

Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea

US Patent 6565880 · Granted May 20, 2003

Assignee

Inventors

View full patent text on Google Patents →